Core Insights - Palantir Technologies has entered a partnership with OneMedNet Corp to enhance healthcare AI and data analytics capabilities using Palantir's Artificial Intelligence Platform [1][2] - The partnership aims to accelerate the use of real-world imaging data in clinical research, leveraging OneMedNet's access to over five billion administrative claims and 131 million clinical exams [2] - This multi-year agreement strengthens Palantir's position in the healthcare sector, following previous collaborations with regulatory bodies and pharmaceutical firms [2][3] Commercial Growth - Palantir reported a year-over-year U.S. commercial revenue growth of 93% and a 64% increase in customer count in its most recent quarter [4] - The company is on track to exceed U.S. commercial revenue guidance of $1.302 billion, indicating a growth rate of at least 85%, with 44% of total revenue coming from commercial sources [5] Stock Performance and Analyst Sentiment - Analysts have raised their price targets for Palantir stock, with a current consensus price target of $141.28, reflecting a 20% downside from its recent closing price [6] - The stock has seen significant growth, up over 137% in 2025 and 20% in the last three months, although growth has slowed to around 4.8% in the last month [8] - Bullish options activity indicates confidence among traders, particularly with higher call volumes at strike prices between $180 and $200 [10] Upcoming Earnings - Palantir is set to report earnings on November 3, with expectations that a strong report could reignite stock momentum [9] - There is a noted increase in short interest in PLTR stock, which could lead to downward pressure if earnings do not meet expectations [11]